Gender-Affirming Estrogen Therapy in Migraine with Aura

Stroke Risk Evidence

Women with migraine with aura who use estrogen-containing contraceptives have a 7-fold increased risk of ischemic stroke (RR 7.02; 95% CI 1.51-32.68) compared to non-users 1, 2
This risk is particularly pronounced in individuals under age 45 (RR 3.65; 95% CI 2.21-6.04) 1, 3
Migraine with aura alone increases stroke risk (RR 2.51; 95% CI 1.52-4.14), and estrogen compounds this baseline elevation 1
High migraine frequency (more than weekly) in those with aura further amplifies ischemic stroke risk (HR 4.25; 95% CI 1.36-13.29) 1, 5
The absolute risk translates to approximately 4 additional intracranial hemorrhage events per 10,000 women per year 2, 4

The American Heart Association/American Stroke Association explicitly recommends against using estrogen-containing contraceptives in individuals with migraine with aura 4
The American College of Obstetricians and Gynecologists and American Headache Society both classify combined hormonal contraceptives as contraindicated in migraine with aura due to increased stroke risk 3

Absolutely prohibit tobacco use - smoking combined with migraine and estrogen creates catastrophic stroke risk (RR 9.03; 95% CI 4.22-19.34) 1, 2
Screen for and aggressively manage hypertension 3
Evaluate for thrombophilia, diabetes, and hyperlipidemia before initiating therapy 3

Consider anti-androgen therapy alone (spironolactone, GnRH agonists) without exogenous estrogen 6
Consider surgical interventions that may reduce the need for high-dose hormone therapy 6
Consider progesterone supplementation, which does not carry the same stroke risk as estrogen 6

Gender-affirming hormone therapy is medically necessary for many transgender individuals and improves quality of life and psychological distress associated with gender dysphoria 6

Assess aura frequency - high frequency (>weekly) represents highest risk 1, 5
Screen for additional stroke risk factors - tobacco, hypertension, thrombophilia, age <45 1, 3
If 2+ additional risk factors present: strongly recommend against estrogen therapy 2, 3
Initiate migraine prophylaxis - propranolol 80-160 mg daily or topiramate 50-100 mg daily to reduce aura frequency 3